Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
diabetic macular edema treatment
market6 mentionslast seen Oct 19, 2026
Retinal disease indication for BGE-102.
Relationships 5
- DURAVYUapplies todiabetic macular edema treatment99% confidence2 sources
- 4D-150applies todiabetic macular edema treatment96% confidence1 source
- BGE-102applies todiabetic macular edema treatment96% confidence1 source
- SZN-8141applies todiabetic macular edema treatment95% confidence1 source
- tabirafusp-tedapplies todiabetic macular edema treatment91% confidence1 source
Relationship
DURAVYUapplies todiabetic macular edema treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 19, 2026EyePoint, Inc. 8-K: Item 2.02: Results of Operations and Financial Condition; Item 2.05: Cost Associated with Exit or Disposal Activities; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME)
- filingSEC EDGAROct 19, 2026EyePoint, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME)